Proliferative retinopathy and retinal detachment in pediatric atypical hemolytic uremic syndrome

Zujaja Tauqeer1, Kandace L Gollomp2, Peter Bracha3

  • 1Scheie Eye Institute, University of Pennsylvania, Philadelphia; Division of Pediatric Ophthalmology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.

Insights

A pediatric patient with atypical hemolytic uremic syndrome developed severe vision loss due to proliferative retinopathy and retinal detachments. This case highlights the ocular complications associated with this rare condition in children.

Area of Science:

  • Ophthalmology
  • Pediatrics
  • Nephrology

Background:

  • Atypical hemolytic uremic syndrome (aHUS) is a rare thrombotic microangiopathy.
  • Ocular manifestations in pediatric aHUS are not well-documented.
  • Previous ocular history included chronic retinal detachment and neovascularization.

Observation:

  • A 14-year-old boy with aHUS presented with decreased vision, flashes, and floaters in his left eye.
  • Examination revealed a new combined tractional-rhegmatogenous retinal detachment in the left eye.
  • Despite surgical intervention, progressive retinal and optic nerve ischemia occurred.

Findings:

  • This is the first reported case of proliferative retinopathy and combined tractional-rhegmatogenous retinal detachments in a pediatric patient with aHUS.
  • The patient experienced irreversible vision loss to light perception in the affected eye.
  • The case underscores the potential for severe, sight-threatening ocular complications in pediatric aHUS.

Implications:

  • Early recognition and management of ocular symptoms in pediatric aHUS are crucial.
  • Further research is needed to understand the pathogenesis of ocular complications in aHUS.
  • This case emphasizes the importance of a multidisciplinary approach involving ophthalmologists, nephrologists, and hematologists.

Related Concept Videos

Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
94
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
22
Acute Kidney Injury II: Pathophysiology01:29

Acute Kidney Injury II: Pathophysiology

Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
197
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
31